Palonosetron in Pediatric Patients: A Single-Center, Retrospective
Evaluation of Policy and Clinical Practice Guideline Discordance
Pediatric clinical practice guidelines (CPGs) on chemotherapy-induced
vomiting (CIV) control were adapted for use at our institution.
Palonosetron use was limited due to cost. The primary objective of this
study was to determine the extent that palonosetron use was discordant
with the institutional policy and CPG. We conducted a retrospective
review of pediatric patients who received palonosetron when receiving
chemotherapy at SickKids between July 1 st, 2019, and
June 30 th, 2020. Most (72%) palonosetron doses were
discordant with institutional policy; 27% were discordant with the CPG.
Our institutional policy has since been updated and is now more aligned
with the CPG.